Latest Freenome News & Updates

See the latest news and media coverage for Freenome. We track all announcements, press releases, and industry mentions in real time, all in one place.

Freenome

Biotech company developing blood tests for early cancer detection

freenome.com

Headquarters: Brisbane, United States
Founded year: 2014
Company type: Private company
Number of employees: 400–500
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Freenome

In short: Freenome received FDA approval for its SimpleScreen CRC blood test and debuted as a public company on the Nasdaq, raising over $300 million.

Company announcements

July 31 Freenome

Freenome celebrated FDA approval, IPO, and test results

The company's SimpleScreen CRC test received FDA approval, its stock began trading on Nasdaq, and an updated version showed improved detection of precancerous lesions.

July 27 Freenome

Freenome's SimpleScreen CRC receives FDA approval

Abbott will commercialize the test in the U.S., expanding colorectal cancer screening options for millions of overdue Americans.

July 20 Freenome

Freenome debuts as a publicly traded company for blood-based cancer detection

The company raised over $300 million and will trade on Nasdaq under FRNM starting July 21, 2026.

July 9 Freenome

Freenome announces top-line results from colorectal cancer screening study

The SimpleScreen CRC test met primary and secondary endpoints with 80.4% sensitivity for cancer and 90% specificity for no findings on colonoscopy.

Media coverage

July 27 Reuters

FDA approves Freenome's blood test for colorectal cancer screening

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the...

July 20 Markets Insider

Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection

Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol 'FRNM' on July 21, 2026 -- Gross proceeds...

July 13 Yahoo Finance

Freenome colorectal cancer test data improve on earlier results

The new study results could make Abbott, which has an agreement with Freenome to market the...

July 9 HCP Live

SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study | HCPLive

Freenome reported updated SimpleScreen CRC results showing 80.4% colorectal cancer sensitivity and 90% specificity.

Never miss news about Freenome

Track Freenome and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Freenome competitors & trending companies

Browse news for competitors to Freenome and other trending companies.